Related Experiment Video

Updated: Aug 24, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

[Diagnosing the mild cognitive impairment stage of Alzheimer's disease]

Masahiro Maruyama1, Toshifumi Matsui, Haruko Tanji

  • 1Department of Gerontology and Respiratory Medicine, Tohoku University Hospital.

Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica
|May 29, 2004
PubMed

Insights

Cerebrospinal fluid total-tau protein (CSF/total-tau) effectively diagnosed amnestic mild cognitive impairment (MCI). Stable MCI showed normal CSF/total-tau with white matter lesions, unlike progressive MCI, which may precede Alzheimer's Disease.

Area of Science:

  • Neurology
  • Biochemistry
  • Medical Imaging

Context:

  • Early diagnosis of Alzheimer's Disease (AD) is crucial for therapeutic development.
  • Mild cognitive impairment (MCI), particularly amnestic MCI, is a significant predictor of AD conversion.
  • Distinguishing between stable and progressive MCI is essential for patient management and prognosis.

Purpose:

  • To evaluate the diagnostic accuracy of cerebrospinal fluid total-tau protein (CSF/total-tau), CSF amyloid beta 1-42 protein (CSF/A beta 1-42), and SPECT-based posterior cingulate cortex cerebral blood flow in identifying amnestic MCI.
  • To differentiate between stable and progressive MCI using CSF/total-tau levels and MRI-detected periventricular white matter lesions (PWML).

Summary:

  • CSF/total-tau demonstrated the highest accuracy in distinguishing between normal cognition and amnestic MCI.
  • Progressive MCI was characterized by elevated CSF/total-tau and minimal PWML, suggesting an early AD stage.
  • Stable MCI was associated with normal CSF/total-tau and significant PWML, indicative of ischemic changes.

Impact:

  • Provides valuable biomarkers for early and accurate diagnosis of amnestic MCI.
  • Offers insights into the differential diagnosis of MCI subtypes, aiding in predicting disease progression.
  • Highlights the potential of CSF/total-tau and MRI findings in understanding the pathophysiology of MCI and its transition to AD.

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.